Schisandrin
Based on 4 publication(s) in Google Scholar
Schisandrin (Schizandrin), a dibenzocyclooctadiene lignan, is isolated from the fruit of Schisandra chinensis Baill. Schisandrin exhibits antioxidant, hepatoprotective, anti-cancer and anti-inflammatory activities. Schisandrin also can reverses memory impairment in rats.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.91%
- CAS No.: 7432-28-2
- Formule: C24H32O7
- Masse moléculaire:432.51
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-N0693
Schisandrin ACytochrome P450 Inhibitor -
HY-N0694
Schisantherin ANF-κB Inhibitor -
HY-N0691R
Schisandrin (Standard)Autophagy Inducer -
HY-N0089
Schisandrin BAntioxidant -
HY-N0005
Curcuminp300 Histone Acetylatransferase Inhibitor -
HY-N0014
IcariinPPAR Activator -
HY-N0692
Schisandrol BHepato-protective Agent -
HY-N0678
IcaritinApoptosis Inducer -
HY-N0690
Schisandrin CBioactive Lignan -
HY-10585
Valproic acidHDAC Inhibitor -
HY-117037
FR900359Gαq/11/14 Inhibitor -
HY-N0635
Prim-O-glucosylcimifuginCOX Inhibitor
Publications Citing Use of MedChemExpress (MCE) Schisandrin
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
WB
-
Apoptosis Analysis
-
Bio/Physico-chemical Assay
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
20.7 μM
Compound: Schizandrin
|
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| A549 | IC50 |
21.65 μM
Compound: 1
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 29501940] |
| A549 | IC50 |
8.5 μM
Compound: 1
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552] |
| DU-145 | IC50 |
13.09 μM
Compound: 1
|
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
|
[PMID: 29501940] |
| DU-145 | IC50 |
5.38 μM
Compound: 1
|
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552] |
| H9 | IC50 |
>58 μM
Compound: schisandrin
|
Cytotoxicity against human H9 cells after 4 days
Cytotoxicity against human H9 cells after 4 days
|
[PMID: 17190445] |
| HCT-15 | IC50 |
50.2 μM
Compound: Schizandrin
|
Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
Antiproliferative activity against human HCT15 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| HEK293 | IC50 |
80.47 μM
Compound: 1
|
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HEK293 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552] |
| HEK293 | IC50 |
81.74 μM
Compound: 1
|
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay
|
[PMID: 29501940] |
| HeLa | IC50 |
>100 μM
Compound: 5
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 23237974] |
| HeLa | IC50 |
28.56 μM
Compound: 1
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 29501940] |
| HeLa | IC50 |
5.06 μM
Compound: 1
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 32631552] |
| HL60/ADR | IC50 |
0.5 ng/mL
Compound: Schisandrol A
|
TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of VCR transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| HL60/ADR | IC50 |
3135 ng/mL
Compound: Schisandrol A
|
TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of VP-16 transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| HL60/ADR | IC50 |
54 ng/mL
Compound: Schisandrol A
|
TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)
TP_TRANSPORTER: inhibition of DNR transport in HL60/ADR cells (overexpression of MRP1)
|
[PMID: 17129588] |
| K562 | IC50 |
25 μM
Compound: Schizandrin
|
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
Antiproliferative activity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 18063366] |
| Lewis lung carcinoma cell line | IC50 |
>100 μM
Compound: 5
|
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
|
[PMID: 23237974] |
| MCF7 | IC50 |
32.56 μM
Compound: 1
|
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29501940] |
| MDA-MB-231 | IC50 |
61.5 μM
Compound: Schizandrin
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| SK-HEP1 | IC50 |
71.3 μM
Compound: Schizandrin
|
Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay
Antiproliferative activity against human SK-HEP1 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| SMMC-7721 | IC50 |
>100 μM
Compound: 5
|
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 23237974] |
| SNU-638 | IC50 |
21.1 μM
Compound: Schizandrin
|
Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay
Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| T47D | IC50 |
19.8 μM
Compound: Schizandrin
|
Antiproliferative activity against human T47D cells after 72 hrs by SRB assay
Antiproliferative activity against human T47D cells after 72 hrs by SRB assay
|
[PMID: 18063366] |
| U-87MG ATCC | IC50 |
>100 μM
Compound: 5
|
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
Cytotoxicity against human U87 cells after 72 hrs by MTT assay
|
[PMID: 23237974] |
In Vitro
Schisandrin (10-100 μM; pretreated for 2 h) inhibits LPS-stimulated NO production, iNOS protein and mRNA expression in a dose-dependent manner in RAW 264.7 cells[1].
Schisandrin (25-100 μM; pretreated for 2 h) inhibits prostaglandin E2 production, COX-2 protein and mRNA expression in LPS-stimulated RAW 264.7 macrophages[1].
Schisandrin inhibits the SK-HEP-1, SNU-638, and T47D cells proliferation, with IC50s of 42.0, 53.1, and 40.0 μM, respectively[3].
Schisandrin (10-60 μM; 48 h) enhances Doxorubicin -induced apoptosis and selectively reverses MCF-7/DOX resistance[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 macrophages
-
Concentration:12.5, 25, 50, 100 μM
-
Incubation Time:Pretreated for 2 h and then incubated with LPS (1 μg/mL) for 18 h
-
Result:Markedly decreased iNOS protein expression a dose-dependent manner.
Significantly inhibited COX-2 protein expression.
In Vivo
Schisandrin (1-10 mg/kg; a single p.o.) significantly reverses the Scopolamine-induced impairment of spatial memory and passive avoidance response, and enhances tremors induced by Oxotremorine in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ICR mice (4-weeks) were treated with λ-carrageenan by intraperitoneal injection into the right hind paw[1]
-
Dosage:100, 200 mg/kg
-
Administration:A single i.p.
-
Result:Inhibited paw edema by 33.43 % (100 mg/kg) and 57.38 % (200 mg/kg) at 3 h.
Chemical Information
-
CAS No. 7432-28-2
-
Appearance Solid
-
Masse moléculaire 432.51
-
Formule C24H32O7
-
Color White to light yellow
-
SMILES
O[C@]1(C)[C@@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C1
-
Synonyms
Schizandrin; Schizandrol; Schizandrol-A
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Enhanced Glycolysis-Driven Histone H3K18 Lactylation Regulates Epileptogenesis by Modulating the E3 Ubiquitin Ligase COP1. [Abstract]2026 May 29:e16985. PMID: 42210782 -
Eur J Pharmacol
Schizandrin A enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB signaling in non-small cell lung cancer. [Abstract]2019 Jul 15:855:10-19. PMID: 31028739 -
Int Immunopharmacol
Schisandrin treatment suppresses the proliferation, migration, invasion, and inflammatory responses of fibroblast-like synoviocytes from rheumatoid arthritis patients and attenuates synovial inflammation and joint destruction in CIA mice. [Abstract]2023 Sep:122:110502. PMID: 37390648 -
J Ovarian Res
Exploring the mechanism of Schisandra rubriflora in the treatment of polycystic ovary syndrome based on network pharmacology and molecular docking. [Abstract]2025 Jan 28;18(1):16. PMID: 39875917
Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]
The viability of KGN cells treated with Schisandrin at different concentrations (0, 1.25, 2.5, 5, 10 and 20 µM) for 24 h was detected by CCK-8 method.
Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]
The mRNA expression levels of IL-1β, IL-6 and iNOS in KGN cells were detected by RT-qPCR treated with Schisandrin (20 μM).
Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]
The protein expression levels of Bcl-2 and Bax were detected by Western blot treated with Schisandrin (20 μM).
Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]
Apoptosis was assessed by flow cytometry treated with Schisandrin (20 μM).
Schisandrin purchased from MedChemExpress. Usage Cited in: J Ovarian Res. 2025 Jan 28;18(1):16. [Abstract]
The levels of MDA and SOD were detected by the corresponding detection kit treated with Schisandrin (20 μM).
Solvant et solubilité
In Vitro:
DMSO : 200 mg/mL (462.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.28 mg/mL (0.65 mM); Clear solution
This protocol yields a clear solution of ≥ 0.28 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (2.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Guo LY, et, al. Anti-inflammatory effects of schisandrin isolated from the fruit of Schisandra chinensis Baill. Eur J Pharmacol. 2008 Sep 4;591(1-3):293-9. [Content Brief]
[2]. Egashira N, et, al. Schizandrin reverses memory impairment in rats. Phytother Res. 2008 Jan;22(1):49-52. [Content Brief]
[3]. Min HY, et, al. Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg Med Chem Lett. 2008 Jan 15;18(2):523-6. [Content Brief]
[4]. Zhang ZL, et, al. Schisandrin A reverses doxorubicin-resistant human breast cancer cell line by the inhibition of P65 and Stat3 phosphorylation. Breast Cancer. 2018 Mar;25(2):233-242. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3121 mL | 11.5604 mL | 23.1209 mL | 57.8021 mL |
| 5 mM | 0.4624 mL | 2.3121 mL | 4.6242 mL | 11.5604 mL | |
| 10 mM | 0.2312 mL | 1.1560 mL | 2.3121 mL | 5.7802 mL | |
| 15 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8535 mL | |
| 20 mM | 0.1156 mL | 0.5780 mL | 1.1560 mL | 2.8901 mL | |
| 25 mM | 0.0925 mL | 0.4624 mL | 0.9248 mL | 2.3121 mL | |
| 30 mM | 0.0771 mL | 0.3853 mL | 0.7707 mL | 1.9267 mL | |
| 40 mM | 0.0578 mL | 0.2890 mL | 0.5780 mL | 1.4451 mL | |
| 50 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.1560 mL | |
| 60 mM | 0.0385 mL | 0.1927 mL | 0.3853 mL | 0.9634 mL | |
| 80 mM | 0.0289 mL | 0.1445 mL | 0.2890 mL | 0.7225 mL | |
| 100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.5780 mL |
Schisandrin Related Classifications
HY-N0691 Related Classifications
Powered by Bioz